Patients with advanced bladder cancer benefit from anti-PD-L1 immunotherapy from balar Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Balar presents at ASCO 2016, results from a non-randomised phase II trial which showed that anti-PD-L1 immunotherapy atezolizumab is effective in patients with previously untreated advanced bladder cancer and not eligible for the standard treatment with cisplatin.
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)